Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGNX Regenxbio

Post-Mkt 12-26 16:49:53 EST

14.16

-0.30

-2.07%

盘后14.16

+0.000.00%

16:10 EST

High14.42	Low13.89	Vol276.51K
Open14.39	D1 Closing14.46	Amplitude3.67%
Mkt Cap716.82M	Tradable Cap586.55M	Total Shares50.62M
T/O3.90M	T/O Rate0.67%	Tradable Shares41.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio","latestPrice":14.16,"timestamp":1766782800000,"preClose":14.46,"halted":0,"volume":276508,"hourTrading":{"tag":"盘后","latestPrice":14.16,"preClose":14.16,"latestTime":"16:10 EST","volume":15285,"amount":216435.6,"timestamp":1766783404166},"delay":0,"floatShares":41423137,"shares":50623086,"eps":-3.46438,"marketStatus":"Post-Mkt","change":-0.3,"latestTime":"12-26 16:49:53 EST","open":14.39,"high":14.42,"low":13.89,"amount":3895282.720693,"amplitude":0.036653,"askPrice":14.45,"askSize":100,"bidPrice":13.9,"bidSize":65,"shortable":3,"etf":0,"ttmEps":-3.46438,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766797200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":14.46,"preHourTrading":{"tag":"盘前","latestPrice":14.4,"preClose":14.46,"latestTime":"09:29 EST","volume":100,"amount":1440,"timestamp":1766759399999},"postHourTrading":{"tag":"盘后","latestPrice":14.16,"preClose":14.16,"latestTime":"16:10 EST","volume":15285,"amount":216435.6,"timestamp":1766783404166},"volumeRatio":0.458335,"impliedVol":0.797,"impliedVolPercentile":0.532},"requestUrl":"/m/hq/s/RGNX","defaultTab":"news","newsList":[{"id":"2593549018","title":"REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593549018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593549018?lang=en_us&edition=fundamental","pubTime":"2025-12-23 18:33","pubTimestamp":1766486034,"startTime":"0","endTime":"0","summary":"REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgnx/regenxbio/news/regenxbio-inc-nasdaqrgnx-surges-27-yet-its-low-ps-is-no-reas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgnx/regenxbio/news/regenxbio-inc-nasdaqrgnx-surges-27-yet-its-low-ps-is-no-reas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","USJW.SI","BK4505","SQQQ","BK4139",".IXIC","QID","NQmain","PSQ","TSYW.SI","QLD","USAW.SI","RGNX","NVIW.SI","MNQmain","BK4563"],"gpt_icon":1},{"id":"2591219621","title":"REGENXBIO Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2591219621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591219621?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:00","pubTimestamp":1765832400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 16:00 ET (21:00 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4563","BK4505"],"gpt_icon":0},{"id":"2586260298","title":"BRIEF-Regenxbio Files For Mixed Shelf Of Up To $300 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260298?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:18","pubTimestamp":1764191883,"startTime":"0","endTime":"0","summary":"BRIEF-Regenxbio Files For Mixed Shelf Of Up To $300 Million - SEC FilingNov 26 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILINGSource text: [ID:n0001193125-25-300539]Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4505","BK4563"],"gpt_icon":0},{"id":"2586260289","title":"Regenxbio Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260289?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:16","pubTimestamp":1764191817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4563","RGNX","BK4139"],"gpt_icon":0},{"id":"2584390491","title":"REGENXBIO Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584390491","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584390491?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:41","pubTimestamp":1763642460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 07:41 ET (12:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX"],"gpt_icon":0},{"id":"2584926770","title":"Regenxbio Q3 License & Royalty Revenue USD 23.605 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926770","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926770?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:53","pubTimestamp":1763571208,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Regenxbio Q3 operating expenses USD 82.144 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:03:41.147 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD4pZLLl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","BK4505","RGNX"],"gpt_icon":0},{"id":"2581483507","title":"REGENXBIO Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581483507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581483507?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:33","pubTimestamp":1762543980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 14:33 ET (19:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX"],"gpt_icon":0},{"id":"2581358018","title":"Regenxbio price target raised to $25 from $24 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2581358018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581358018?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:46","pubTimestamp":1762541166,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Regenxbio (RGNX) to $25 from $24 and keeps an Overweight rating on the shares. Published first on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-raised-to-25-from-24-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-raised-to-25-from-24-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0},{"id":"2581888797","title":"RBC Capital Adjusts REGENXBIO Price Target to $19 From $17, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888797","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888797?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:02","pubTimestamp":1762531350,"startTime":"0","endTime":"0","summary":"Price: 11.01, Change: -0.16, Percent Change: -1.43","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGNX"],"gpt_icon":0},{"id":"1116113875","title":"Stock Track | Regenxbio Plummets 5.25% Despite Beating Q3 Estimates as Losses Continue","url":"https://stock-news.laohu8.com/highlight/detail?id=1116113875","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116113875?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:55","pubTimestamp":1762444552,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) shares plummeted 5.25% in pre-market trading on Thursday, despite the company reporting better-than-expected third-quarter results. The biotechnology firm's financial performance...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RGNX"],"gpt_icon":0},{"id":"1153318658","title":"Stock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=1153318658","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153318658?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:04","pubTimestamp":1762434265,"startTime":"0","endTime":"0","summary":"Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RGNX"],"gpt_icon":0},{"id":"2581678530","title":"Regenxbio Q3 revenue rises 23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581678530","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581678530?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:13","pubTimestamp":1762431190,"startTime":"0","endTime":"0","summary":"Regenxbio Q3 revenue rises 23%OverviewRegenxbio Q3 revenue rises to $29.7 mln from $24.2 mln year-over-yearNet loss for Q3 widens to $61.9 mln from $59.6 mln year-over-yearRegenxbio's cash position im","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4139","BK4505"],"gpt_icon":0},{"id":"2581062014","title":"Regenxbio Q3 EPS $(1.20) Beats $(1.33) Estimate, Sales $29.733M Beat $24.125M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062014","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062014?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:09","pubTimestamp":1762430965,"startTime":"0","endTime":"0","summary":"Regenxbio Q3 EPS $(1.20) Beats $(1.33) Estimate, Sales $29.733M Beat $24.125M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682487/regenxbio-q3-eps-1-20-beats-1-33-estimate-sales-29-733m-beat-24-125m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX"],"gpt_icon":0},{"id":"2581412062","title":"Regenxbio Projects Cash Runway Into Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581412062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581412062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:06","pubTimestamp":1762430771,"startTime":"0","endTime":"0","summary":"REGENXBIO Inc. reported that it expects to have $302.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is anticipated to fund its operations into early 2027. This outlook is based on current operational plans and does not include any potential milestone payments from partners or licensees, nor the possible monetization of a priority review voucher tied to the approval of clemidsogene lanparvovec. No significant variation in business performance for the period was disclosed in the financial guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire  on November 06, 2025, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9ZVG68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RGNX","BK4563","BK4139"],"gpt_icon":0},{"id":"2581306213","title":"BRIEF-Regenxbio Q3 License & Royalty Revenue USD 23.605 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581306213","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581306213?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:05","pubTimestamp":1762430745,"startTime":"0","endTime":"0","summary":"BRIEF-Regenxbio Q3 License & Royalty Revenue USD 23.605 Million\n\n\nNov 06 (Reuters) - Regenxbio Q3 operating expenses USD 82.144 million.\n\nQ3 net income USD -61.941 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX22C0B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2581906252","title":"Regenxbio Q3 Operating Expenses USD 82.144 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581906252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581906252?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:05","pubTimestamp":1762430701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX22C0B5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4563","RGNX"],"gpt_icon":0},{"id":"2581706239","title":"Regenxbio Reports Third Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706239?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:05","pubTimestamp":1762430700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA3DFBVS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4505","BK4563","BK4139"],"gpt_icon":0},{"id":"2580975392","title":"Regenxbio Inc  expected to post a loss of $1.31 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580975392","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580975392?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:47","pubTimestamp":1762267628,"startTime":"0","endTime":"0","summary":"Regenxbio Inc  expected to post a loss of $1.31 a share - Earnings Preview Regenxbio Inc RGNX.OQ RGNX.O is expected to  show a fall in quarterly revenue when it reports  results on November 6 for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG24N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4563","RGNX"],"gpt_icon":0},{"id":"2580174042","title":"FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2580174042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580174042?lang=en_us&edition=fundamental","pubTime":"2025-11-03 23:30","pubTimestamp":1762183809,"startTime":"0","endTime":"0","summary":"Stifel analyst Annabel Samimy says that the news regarding FDA’s reversal on the approvability of uniQure’s (QURE) AMT-130 on Phase 1/2 data on the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fdas-uniqure-reversal-unlikely-to-impact-regenxbios-programs-says-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fdas-uniqure-reversal-unlikely-to-impact-regenxbios-programs-says-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","SF","QURE","BK4563","BK4139","BK4127","RGNX","BK4505"],"gpt_icon":0},{"id":"2579117747","title":"BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2579117747","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579117747?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:07","pubTimestamp":1761822472,"startTime":"0","endTime":"0","summary":"BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy ProgramOct 30 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO ANNOUNCES COMPLETION OF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUA50PLVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4505","BK4139","BK4563"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":0.0979},{"period":"1month","weight":0.1823},{"period":"3month","weight":0.5449},{"period":"6month","weight":0.7235},{"period":"1year","weight":0.9541},{"period":"ytd","weight":0.8706}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.077673},{"month":2,"riseRate":0.3,"avgChangeRate":0.019547},{"month":3,"riseRate":0.6,"avgChangeRate":0.015225},{"month":4,"riseRate":0.6,"avgChangeRate":0.035795},{"month":5,"riseRate":0.3,"avgChangeRate":-0.022478},{"month":6,"riseRate":0.6,"avgChangeRate":0.047674},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001741},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.050912}],"exchange":"NASDAQ","name":"Regenxbio","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regenxbio,RGNX,Regenxbio股票,Regenxbio股票老虎,Regenxbio股票老虎国际,Regenxbio行情,Regenxbio股票行情,Regenxbio股价,Regenxbio股市,Regenxbio股票价格,Regenxbio股票交易,Regenxbio股票购买,Regenxbio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction